Bicara Therapeutics clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 1 with a minor change only.

1. Notable

   BCA101 Monotherapy and in Combination Therapy · EGFR-driven…BCA101 Monotherapy and in Combination Therapy · EGFR-driven Advanced Solid Tumors

   Primary completion pushed from Dec 31, 2026 to Oct 31, 2027

   Also in this update: Enrollment increased: 292 → 473 participants; Completion pushed from Jun 1, 2027 to Mar 30, 2028

   Bicara Therapeutics·Phase 1· NCT04429542· Registry history of NCT04429542 on ClinicalTrials.gov (opens the registry)

   Updated Oct 6, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.